← 返回

纵向单细胞和 TCR 库分析表征了 pMMR/MSS 局部晚期直肠癌患者的克隆陷留

英文原题:Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.

查看英文原题

Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.

PubMed 2026/06/30(内容时间) Cell Discov Q1 · IF 16.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

治疗前肿瘤内免疫炎症升高通常与热肿瘤接受免疫检查点抑制剂(ICI)治疗后的更好结局相关。然而,我们在pMMR/MSS局部晚期直肠癌(LARC)患者中观察到一个悖论:与免疫炎症极低的患者相比,基线免疫炎症升高的一部分患者在接受放疗联合ICI治疗后表现出更差的结局。为探究这一反直觉发现,我们对20例接受序贯放疗和ICI治疗(NCT06493240)的pMMR/MSS LARC患者纵向采集的样本进行了配对scRNA-seq和scTCR-seq,样本包括肿瘤活检(治疗前、放疗后和免疫治疗后)以及外周血单个核细胞(治疗前和免疫治疗后)。

我们提出克隆捕获这一概念来解释该现象。具体而言,我们的分析结果揭示,树突状细胞中HLA-DQA2表达升高以及治疗抵抗性肿瘤细胞中GDF15表达上调,与新型肿瘤反应性TCR克隆型的扩增受限相关。

因此,免疫反应主要受限于肿瘤内预先存在的TCR克隆型,尤其是那些在慢性炎症下部分扩增的克隆型,导致ICI治疗后扩增的TCR克隆型主要来源于治疗前的CD8+ T细胞库。通过识别pMMR/MSS LARC微环境的这一特征,我们的研究为理解序贯放疗和ICI治疗耐药提供了一个高分辨率框架。

展开英文摘要原文

Elevated intratumoral immune inflammation prior to treatment is typically associated with better outcomes in hot tumors treated with immune checkpoint inhibitors (ICIs).

However, we observed a paradox in pMMR/MSS locally advanced rectal cancer (LARC) patients, where a subset with elevated baseline immune inflammation exhibited worse outcomes after combined radiotherapy and ICI treatment compared with patients with minimal immune inflammation.

To investigate this counterintuitive finding, we performed paired scRNA-seq and scTCR-seq on longitudinally collected samples, including tumor biopsies (pre-treatment, post-radiotherapy, and post-immunotherapy) and peripheral blood mononuclear cells (pre-treatment and post-immunotherapy), from 20 pMMR/MSS LARC patients treated with sequential radiotherapy and ICI therapy (NCT06493240).

We propose the concept of clonal entrapment to explain this phenomenon. Specifically, our profiling results reveal that increased HLA-DQA2 expression in dendritic cells and upregulated GDF15 expression in treatment-resistant tumor cells correlate with the restricted expansion of novel tumor-reactive TCR clonotypes.

Consequently, the immune response is limited primarily by pre-existing TCR clonotypes within the tumor, especially those partially expanded under chronic inflammation, leading to the expansion of TCR clonotypes derived mainly from pre-treatment CD8 + T cell pools following ICI therapy. By identifying this feature of the pMMR/MSS LARC microenvironment, our study provides a high-resolution framework for understanding resistance to sequential radiotherapy and ICI therapy.

论文信息

作者
Tang Z、Zhu M、Zhao S、Pang D、Cui Y、Lin G、Wu A、Lin Y
第一作者单位
Biomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Peking-Tsinghua Center for Life Sciences (CLS), State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Peking University, Beijing, China.China
通讯作者单位
Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China. shenzhanlong@pku.edu.cn.China
期刊
Cell discovery2026 Jun 30
原文标识
PubMed 42373609 · DOI 10.1038/s41421-026-00900-w